Clinical trials started for TT-034 an injectable hcv tx.
maddie said
Jun 2, 2014
Pretty interesting article about new clinical trial involving one injection of TT-034.
SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) announced that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.
The Phase I/IIa clinical trial is an open label, dose escalation study in a total of 14 patients chronically infected with HCV genotype 1. Initial patient cohorts will be treated with a sub-therapeutic dose of TT-034 to ensure that there are no unexpected safety concerns, before proceeding to higher, potentially therapeutic doses.
Pretty interesting article about new clinical trial involving one injection of TT-034.
SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) announced that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.
The Phase I/IIa clinical trial is an open label, dose escalation study in a total of 14 patients chronically infected with HCV genotype 1. Initial patient cohorts will be treated with a sub-therapeutic dose of TT-034 to ensure that there are no unexpected safety concerns, before proceeding to higher, potentially therapeutic doses.
http://online.wsj.com/article/PR-CO-20140529-906886.html